Antigen News and Research RSS Feed - Antigen News and Research

Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system's B cells, providing a new approach to developing and implementing antigen-presenting cell vaccines. [More]
Mi-Prostate Score improves prostate cancer detection

Mi-Prostate Score improves prostate cancer detection

A new urine-based test improved prostate cancer detection - including detecting more aggressive forms of prostate cancer - compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds. [More]
BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform. [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
Active surveillance appears to be safer management strategy for prostate cancer patients

Active surveillance appears to be safer management strategy for prostate cancer patients

Four studies evaluating effectiveness, trends and other considerations for active surveillance in managing prostate cancer will be presented during the 110th Annual Scientific Meeting of the American Urological Association. [More]
FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology. [More]
Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen. [More]
Australian researchers discover rogue germinal centre B cells that trigger autoimmune disease

Australian researchers discover rogue germinal centre B cells that trigger autoimmune disease

Australian researchers believe they have discovered a group of cells that trigger autoimmune disease, as well as the molecular 'trigger guard' that normally holds them in check. [More]
Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells. [More]
Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics Inc. today announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. [More]
Study shows that periodontal treatment can reduce symptoms of prostatitis

Study shows that periodontal treatment can reduce symptoms of prostatitis

Treating gum disease reduced symptoms of prostate inflammation, called prostatitis, report researchers from Case Western Reserve University School of Dental Medicine and the Departments of Urology and Pathology at University Hospitals Case Medical Center. [More]
Antigen-loaded porous silicon microparticles can boost effectiveness of breast cancer vaccines

Antigen-loaded porous silicon microparticles can boost effectiveness of breast cancer vaccines

The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online). [More]
Protein Sciences, CTH@H to provide Flublok vaccine to home health and hospice agencies in Connecticut

Protein Sciences, CTH@H to provide Flublok vaccine to home health and hospice agencies in Connecticut

Protein Sciences Corporation, along with The Connecticut Association for Healthcare at Home, announced a new partnership today that will bring Flublok influenza vaccine to home health and hospice agencies across the state. As a new affinity partner of CTH@H, Protein Sciences will make Flublok available to CTH@H member agencies for the 2015/16 flu season. [More]

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that activity and tolerance data for its second lead product Col-Treg were presented through a poster presentation at the 2015 ARVO Annual Meeting, May 3-7, 2015, in Denver, Colorado, US. [More]
T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cells are taken from the patient’s blood and then modified using lentivirus, adenovirus or RNA electroporation. The modifications allow us to reprogram T cells to recognize cancer cells. [More]
Novel Ga-68-PSMA-ligand PET/CT effective for early detection of prostate cancer recurrence

Novel Ga-68-PSMA-ligand PET/CT effective for early detection of prostate cancer recurrence

A recent study reported in The Journal of Nuclear Medicine compared use of the novel Ga-68-PSMA-ligand PET/CT with other imaging methods and found that it had substantially higher detection rates of prostate-specific membrane antigen (PSMA) in patients with biochemical recurrence after radical prostatectomy. [More]
Pre-POINT trial raises hope for Type 1 diabetes prevention

Pre-POINT trial raises hope for Type 1 diabetes prevention

Giving oral insulin to children at genetic high risk of diabetes stimulates a regulatory immune response without inducing hypoglycaemia, show the findings of the Pre-POINT study. [More]
Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

Scientists at Texas Biomedical Research Institute have begun work on a nearly $3.4 million study funded by the National Institutes of Health over the next four years to create an attenuated, or weakened, virus that is a hybrid of the papilloma virus and the human immunodeficiency virus, with the potential to jumpstart a body's immune response to develop antibodies against both viruses. [More]

Scientists report efficient way to transform A and B blood into neutral type

Every day, thousands of people need donated blood. But only blood without A- or B-type antigens, such as type O, can be given to all of those in need, and it's usually in short supply. Now scientists are making strides toward fixing the situation. In ACS' Journal of the American Chemical Society, they report an efficient way to transform A and B blood into a neutral type that can be given to any patient. [More]
TDF switch effective in Asian chronic HBV patients

TDF switch effective in Asian chronic HBV patients

Switching therapy to tenofovir disoproxil fumarate is effective in treatment-resistant chronic hepatitis B, show results from a cohort of Asian patients. [More]
Advertisement
Advertisement